Why SCLC Remains One of Oncology’s Most Urgent Unmet Needs

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer diagnoses globally and is defined by an aggressive biology that makes it among the most lethal solid tumours in clinical oncology. The five-year survival rate for extensive-stage SCLC — the form in which the majority of patients are diagnosed — remains below 7%, a figure that has changed only marginally over the past three decades despite advances in immunotherapy and supportive care.

The standard of care for first-line extensive-stage SCLC has been carboplatin or cisplatin combined with etoposide since the 1980s. The addition of immune checkpoint inhibitors — atezolizumab (approved by the FDA in 2019) and durvalumab — provided modest but statistically significant improvements in overall survival, yet median OS in the first-line setting still sits at approximately 13 months. The disease’s propensity for rapid relapse, early development of chemoresistance, and high rate of brain metastasis means that even patients who respond initially face a median progression-free survival of under six months.

This clinical reality has intensified the search for novel mechanisms of action beyond PD-L1 inhibition. Antibody-drug conjugates (ADCs) — which deliver cytotoxic payloads directly to tumour cells via a targeting antibody — have emerged as a leading therapeutic strategy, driven by the success of agents such as trastuzumab deruxtecan in HER2-positive cancers. The question facing the field is whether the same engineering principles can be applied to SCLC’s distinct surface antigen profile. According to data published by WHO, lung cancer remains the leading cause of cancer mortality worldwide, underscoring the scale of the unmet need that successful SCLC ADC development would address.

B7-H3 as an ADC Target: The Science Behind Ifinatamab Deruxtecan

Ifinatamab deruxtecan (I-DXd) is a B7-H3-directed antibody-drug conjugate built on Daiichi Sankyo’s proprietary DXd ADC platform — the same technology underpinning trastuzumab deruxtecan (Enhertu). B7-H3, also known as CD276, is a member of the B7 immune checkpoint protein family and is overexpressed on the surface of SCLC tumour cells at high frequency, making it an attractive and biologically rational target for selective ADC delivery.

The DXd platform uses a cleavable tetrapeptide-based linker that releases the topoisomerase I inhibitor payload (an exatecan derivative, DXd) selectively within the tumour microenvironment following receptor-mediated internalisation. A key pharmacological feature of the platform is its high drug-to-antibody ratio (DAR) of approximately 8, which increases the amount of cytotoxic payload delivered per antibody molecule compared to earlier-generation ADCs. This high DAR, combined with the membrane-permeable nature of DXd, enables a bystander killing effect — whereby released payload can diffuse into and kill neighbouring antigen-negative tumour cells, potentially overcoming the heterogeneous antigen expression that has historically limited ADC efficacy in solid tumours.

The biological rationale for targeting B7-H3 in SCLC is supported by immunohistochemical studies demonstrating high and consistent B7-H3 expression across SCLC tumour specimens, in contrast to the more variable expression of targets such as DLL3. This expression consistency is clinically significant: it suggests that patient selection based on B7-H3 biomarker status may not be required, potentially enabling broad enrolment in the DeLLphi-304 trial without the need for companion diagnostic testing that has complicated the rollout of other ADCs in thoracic oncology. Research published in Nature and related journals has highlighted B7-H3’s dual role as both a tumour antigen and an immune checkpoint modulator, adding mechanistic depth to the rationale for its therapeutic targeting.

From DeLLphi Phase I/II to the Phase III DeLLphi-304 Trial

The DeLLphi clinical programme began with Phase I/II studies that established the safety, tolerability, and preliminary efficacy profile of ifinatamab deruxtecan in relapsed or refractory SCLC — providing the dose-escalation and expansion data required to support advancement into a randomised Phase III setting. The DeLLphi-301 and DeLLphi-302 studies demonstrated objective response rates in previously treated SCLC patients that were considered clinically meaningful relative to historical benchmarks for second- and third-line therapy in this setting.

“The DeLLphi-304 trial represents the first time a B7-H3-targeting antibody-drug conjugate has been evaluated as a first-line combination therapy in extensive-stage small cell lung cancer — a disease where the standard of care has remained essentially unchanged for four decades.”

DeLLphi-304 is a global, randomised, double-blind, placebo-controlled Phase III trial. The study evaluates ifinatamab deruxtecan in combination with carboplatin and etoposide (the current standard backbone chemotherapy) versus carboplatin, etoposide, and placebo as first-line treatment for patients with extensive-stage SCLC. The trial’s primary endpoints are progression-free survival (PFS) and overall survival (OS), with secondary endpoints including objective response rate, duration of response, and patient-reported outcomes.

The trial design reflects lessons from the immunotherapy era in SCLC: both atezolizumab (IMpower133) and durvalumab (CASPIAN) were evaluated in combination with carboplatin/etoposide in the first-line setting, and both demonstrated OS benefit — establishing the combination backbone as a viable platform for adding novel agents. DeLLphi-304 adopts a similar additive strategy, testing whether the ADC’s targeted cytotoxicity can augment the effects of chemotherapy beyond what immune checkpoint inhibition achieves. The trial is co-sponsored by Daiichi Sankyo and MSD (Merck & Co.), reflecting the global collaboration agreement between the two companies that covers multiple DXd ADC assets.

The ADC Patent Landscape Surrounding Ifinatamab Deruxtecan

The intellectual property architecture supporting ifinatamab deruxtecan spans multiple patent families covering the B7-H3 antibody sequence, the DXd linker-payload chemistry, and the manufacturing processes for high-DAR ADC conjugation. Daiichi Sankyo holds foundational patents on the DXd platform technology, with priority dates extending back to the early 2010s — a filing timeline that positions these assets to provide exclusivity protection well into the 2030s across major jurisdictions including the United States, Europe, Japan, and China.

The B7-H3 targeting space has attracted growing patent activity from multiple organisations, reflecting the target’s broad appeal across oncology indications beyond SCLC. Patent filings covering B7-H3-directed antibodies, bispecific constructs, and ADC conjugates have accelerated since approximately 2018, creating a complex freedom-to-operate landscape that drug developers must navigate. The European Patent Office and the USPTO have both seen substantial filing volumes in this area, with claims covering antibody sequences, linker chemistry, and combination therapy methods.

Key patent dimensions in the ifinatamab deruxtecan IP estate include: the anti-B7-H3 antibody variable region sequences; the tetrapeptide-based cleavable linker chemistry; the exatecan derivative (DXd) synthesis and conjugation methods; and method-of-treatment claims covering SCLC and other B7-H3-expressing solid tumours. The breadth of these claims across multiple patent families creates layered protection that is characteristic of Daiichi Sankyo’s ADC portfolio strategy — a strategy that has also been applied to trastuzumab deruxtecan and patritumab deruxtecan (HER3-directed).

Competitive Context: Where DeLLphi-304 Sits in the SCLC Pipeline

DeLLphi-304 enters a first-line SCLC landscape that has seen several high-profile late-stage failures, including rovalpituzumab tesirine (Rova-T), a DLL3-targeting ADC that failed to demonstrate OS benefit in Phase III. The contrast between Rova-T’s failure and the progress of ifinatamab deruxtecan is instructive: Rova-T’s challenges included DLL3 expression heterogeneity, linker-payload toxicity at therapeutic doses, and a narrow therapeutic window. The DXd platform’s superior tolerability profile — demonstrated across multiple ADC programmes — and B7-H3’s more consistent expression across SCLC specimens address two of the three failure modes that undermined Rova-T.

Beyond ifinatamab deruxtecan, the SCLC first-line pipeline includes several other investigational agents in Phase II and Phase III evaluation. Tarlatamab, a DLL3×CD3 bispecific T-cell engager developed by Amgen, received accelerated FDA approval for second-line SCLC in 2024 and is now being evaluated in first-line combinations. Lurbinectedin (Zepzelca) is approved in the second-line setting and has ongoing first-line combination studies. The convergence of multiple novel mechanisms — ADCs, bispecifics, and small molecules — in the SCLC first-line setting means that DeLLphi-304’s results will be interpreted in a rapidly evolving competitive context.

From an innovation intelligence perspective, the SCLC ADC space is characterised by high patent density around established targets (DLL3, B7-H3) and growing activity around emerging targets including CEACAM5, TROP2, and PARP. Organisations seeking to enter this space must conduct rigorous freedom-to-operate analysis to identify viable claim differentiation strategies. The PatSnap pharmaceutical intelligence platform provides access to over 2 billion data points across patent, clinical trial, and regulatory databases — enabling R&D teams to map the competitive landscape with precision. According to ClinicalTrials.gov, the number of registered SCLC trials has grown substantially in the past five years, reflecting renewed industry interest in this historically underinvested indication.

The strategic significance of DeLLphi-304 extends beyond SCLC. A positive Phase III result would validate the DXd platform’s applicability to neuroendocrine tumours and high-B7-H3-expressing solid tumours more broadly, potentially opening new indication expansion pathways for ifinatamab deruxtecan. It would also reinforce the commercial rationale for the Daiichi Sankyo–MSD collaboration, which spans five DXd ADC assets and represents one of the largest oncology partnership agreements in recent pharmaceutical history. For IP strategists and R&D leaders, monitoring the DeLLphi-304 readout and the associated patent prosecution activity will be essential for anticipating the next phase of competitive dynamics in the ADC space. The PatSnap Insights blog provides ongoing analysis of ADC patent trends and clinical development milestones.